Skip to main content
Premium Trial:

Request an Annual Quote

Agendia to Use Rubicon's WGA Kits in Breast Cancer Dx Tests

Premium

Agendia will use Rubicon Genomics' whole-genome RNA amplification technology in its breast cancer diagnostic tests, Rubicon said today.

Under a clinical supply agreement, Agendia will apply Rubicon's TransPlex technology to analyze formalin-fixed, paraffin-embedded patient samples on Agendia's Symphony suite of breast cancer diagnostics.

RNA or DNA extracted from FFPE samples is highly fragmented and often contains only small amounts of usable DNA or RNA, which may be insufficient for analysis. Rubicon's TransPlex and GenomePlex amplification kits are members of Rubicon's OmniPlex family of technologies, and have been shown to be able to overcome these problems and deliver sufficient quantities of high-quality nucleic acids to enable accurate and consistent analyses, the company said.

In a statement, Rubicon CEO James Koziarz called the deal an important milestone for his firm. "This supply agreement with cancer diagnostics pioneer Agendia represents our first large-scale commercial partnership with a provider of clinical diagnostic tests, and we expect it to be the first of many going forward," he said.

Financial and other terms of the deal were not disclosed.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.